QUININE ASCORBATE

US Previously Marketed

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C20H24N2O2.2C6H8O6
Molecular Weight	676.665
Optical Activity	UNSPECIFIED
Defined Stereocenters	8 / 8
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO.[H][C@@]2(OC(=O)C(O)=C2O)[C@@H](O)CO.[H][C@]3(C[C@@H]4CCN3C[C@@H]4C=C)[C@H](O)C5=C6C=C(OC)C=CC6=NC=C5

InChI

InChIKey=CJHQUYQRCLIWSW-JPGAVJPLSA-N

InChI=1S/C20H24N2O2.2C6H8O6/c1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18;2*7-1-2(8)5-3(9)4(10)6(11)12-5/h3-6,8,11,13-14,19-20,23H,1,7,9-10,12H2,2H3;2*2,5,7-10H,1H2/t13-,14-,19-,20+;2*2-,5+/m000/s1

HIDE SMILES / InChI

Molecular Formula	C6H8O6
Molecular Weight	176.1241
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	C20H24N2O2
Molecular Weight	324.4168
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	4 / 4
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=310&showFR=1 | https://www.ncbi.nlm.nih.gov/pubmed/8008450 | https://www.drugs.com/ppa/quinine.html

Quinine ascorbate is a salt of antimalarial drug quinine and ascorbic acid (vitamin C). Ascorbate reduces the potency of quinolone-containing anti-malarial drugs. Quinine ascorbate was marketed as a component of over-the-counter smoking deterrent products but was not recognized as safe by the FDA regulation in 1993.

Approval Year

C_max

Value	Dose	Analyte	Population
10.6 μg/mL EXPERIMENT https://www.sciencedirect.com/science/article/abs/pii/S0022347685806922	300 mg/m² single, intramuscular dose: 300 mg/m² route of administration: Intramuscular experiment type: SINGLE co-administered:	QUININE serum	Homo sapiens population: UNHEALTHY age: CHILD sex: UNKNOWN food status: UNKNOWN
9.7 μg/mL EXPERIMENT https://www.sciencedirect.com/science/article/abs/pii/S0022347685806922	300 mg/m² single, intravenous dose: 300 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered:	QUININE serum	Homo sapiens population: UNHEALTHY age: CHILD sex: UNKNOWN food status: UNKNOWN
10.3 μg/mL EXPERIMENT https://www.sciencedirect.com/science/article/abs/pii/S0022347685806922	300 mg/m² single, intragastric dose: 300 mg/m² route of administration: Intragastric experiment type: SINGLE co-administered:	QUININE serum	Homo sapiens population: UNHEALTHY age: CHILD sex: UNKNOWN food status: UNKNOWN
11.3 μg/mL EXPERIMENT https://www.sciencedirect.com/science/article/abs/pii/S0022347685806922	300 mg/m² 2 times / day multiple, intramuscular dose: 300 mg/m² route of administration: Intramuscular experiment type: MULTIPLE co-administered:	QUININE serum	Homo sapiens population: UNHEALTHY age: CHILD sex: UNKNOWN food status: UNKNOWN
3.2 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021799lbl.pdf	8.7 mg/kg single, oral dose: 8.7 mg/kg route of administration: Oral experiment type: SINGLE co-administered:	QUININE unknown	Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
8.4 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021799lbl.pdf	10 mg/kg single, oral dose: 10 mg/kg route of administration: Oral experiment type: SINGLE co-administered:	QUININE unknown	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
87.2 μg × h/mL EXPERIMENT https://www.sciencedirect.com/science/article/abs/pii/S0022347685806922	300 mg/m² single, intramuscular dose: 300 mg/m² route of administration: Intramuscular experiment type: SINGLE co-administered:	QUININE serum	Homo sapiens population: UNHEALTHY age: CHILD sex: UNKNOWN food status: UNKNOWN
90.5 μg × h/mL EXPERIMENT https://www.sciencedirect.com/science/article/abs/pii/S0022347685806922	300 mg/m² single, intravenous dose: 300 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered:	QUININE serum	Homo sapiens population: UNHEALTHY age: CHILD sex: UNKNOWN food status: UNKNOWN
95.4 μg × h/mL EXPERIMENT https://www.sciencedirect.com/science/article/abs/pii/S0022347685806922	300 mg/m² single, intragastric dose: 300 mg/m² route of administration: Intragastric experiment type: SINGLE co-administered:	QUININE serum	Homo sapiens population: UNHEALTHY age: CHILD sex: UNKNOWN food status: UNKNOWN
28 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021799lbl.pdf	8.7 mg/kg single, oral dose: 8.7 mg/kg route of administration: Oral experiment type: SINGLE co-administered:	QUININE unknown	Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
73 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021799lbl.pdf	10 mg/kg single, oral dose: 10 mg/kg route of administration: Oral experiment type: SINGLE co-administered:	QUININE unknown	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
8.4 h EXPERIMENT https://www.sciencedirect.com/science/article/abs/pii/S0022347685806922	300 mg/m² single, intramuscular dose: 300 mg/m² route of administration: Intramuscular experiment type: SINGLE co-administered:	QUININE serum	Homo sapiens population: UNHEALTHY age: CHILD sex: UNKNOWN food status: UNKNOWN
12.5 h EXPERIMENT https://www.sciencedirect.com/science/article/abs/pii/S0022347685806922	300 mg/m² single, intravenous dose: 300 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered:	QUININE serum	Homo sapiens population: UNHEALTHY age: CHILD sex: UNKNOWN food status: UNKNOWN
13.1 h EXPERIMENT https://www.sciencedirect.com/science/article/abs/pii/S0022347685806922	300 mg/m² single, intragastric dose: 300 mg/m² route of administration: Intragastric experiment type: SINGLE co-administered:	QUININE serum	Homo sapiens population: UNHEALTHY age: CHILD sex: UNKNOWN food status: UNKNOWN
9.8 h EXPERIMENT https://www.sciencedirect.com/science/article/abs/pii/S0022347685806922	300 mg/m² 2 times / day multiple, intramuscular dose: 300 mg/m² route of administration: Intramuscular experiment type: MULTIPLE co-administered:	QUININE serum	Homo sapiens population: UNHEALTHY age: CHILD sex: UNKNOWN food status: UNKNOWN

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1709 inhibitor 1579 inducer 768	substrate 1010	substrate 1193 inhibitor 1837

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
OCTN1 29 OCT3 149 OCTN2 66 OCT2 638 OATP1B1 781 OATP1B3 700 OATP2B1 122 OCT1 506 BSEP 401 MRP2 367 MRP3 157 MRP4 203 P-gp 1437 OATP1A2 35 CYP2C8 901 CYP2C19 1463 CYP1A1 110	CYP2C19 985 CYP2E1 648 CYP3A7 110 P-gp 1527 CYP3A5 391 CYP1A2 1032 CYP2C8 688 OCT2 348 OCT1 322	CYP1A2 689

Drug as perpetrator

Target	Modality	Activity
BSEP 402	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/, https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw2MDIwIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE3MCJ9fQ%3D%3D	no [IC50 >133 uM]
MRP2 459	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/, https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1NzQ4IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE3MCJ9fQ%3D%3D	no [IC50 >133 uM]
MRP3 208	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/, https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1OTE4IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE3MCJ9fQ%3D%3D	no [IC50 >133 uM]
MRP4 237	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/, https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNzQzMTI4IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE3MCJ9fQ%3D%3D	no [IC50 >133 uM]
OATP1B3 709	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/22541068/, https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNzQzMTIxIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE3MCJ9fQ%3D%3D	no [Inhibition 20 uM]
OATP2B1 125	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/22541068/, https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNzQzMTI0IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE3MCJ9fQ%3D%3D	no [Inhibition 20 uM]
OCTN1 29	inhibitor 3240 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwyMDczNjY4IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE3MCJ9fQ%3D%3D	weak
CYP2D6 1875	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/16610785/, https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwyODkiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMMTcwIn19	yes [IC50 1.8 uM]
P-gp 1626	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/11716514/, https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw0MzAyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE3MCJ9fQ%3D%3D	yes [IC50 22.6 uM]
OCT1 523	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/18788725/,https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1Njg1IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE3MCJ9fQ%3D%3D	yes [IC50 51.6 uM]
OATP1B1 796	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/22541068/, https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNjk3NjY4IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE3MCJ9fQ%3D%3D	yes [Inhibition 20 uM]
CYP2C8 955	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/11136296/, https://go.drugbank.com/drugs/DB00468	yes [Inhibition 80 uM]
OCT2 639	inhibitor 3240 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNzQzMTIyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE3MCJ9fQ%3D%3D	yes [Ki 3.4 uM]
CYP1A1 218	inhibitor 3240 Sources: https://go.drugbank.com/drugs/DB00468	yes
CYP1A2 1673	inducer 1542 Sources: https://go.drugbank.com/drugs/DB00468	yes
CYP2C19 1537	inhibitor 3240 Sources: https://go.drugbank.com/drugs/DB00468	yes
CYP3A4 1909	inducer 1542 Sources: https://go.drugbank.com/drugs/DB00468	yes
CYP3A4 1909	inhibitor 3240 Sources: https://go.drugbank.com/drugs/DB00468	yes
OATP1A2 35	inhibitor 3240 Sources: https://go.drugbank.com/drugs/DB00468	yes
OCT3 149	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/28811134/, https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwyMDczNjczIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE3MCJ9fQ%3D%3D	yes
OCTN2 71	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/10525100/, https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwyMDczNjkzIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE3MCJ9fQ%3D%3D	yes

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP1A2 1032	substrate 3326 Sources: https://s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/632/original/FDA_label_Quinine.pdf?1537805198	likely
CYP2C19 985	substrate 3326 Sources: https://s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/632/original/FDA_label_Quinine.pdf?1537805198	likely
CYP2C8 688	substrate 3326 Sources: https://s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/632/original/FDA_label_Quinine.pdf?1537805198	likely
CYP2C9 1010	substrate 3326 Sources: https://s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/632/original/FDA_label_Quinine.pdf?1537805198	likely
CYP2E1 648	substrate 3326 Sources: https://s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/632/original/FDA_label_Quinine.pdf?1537805198	likely
P-gp 1527	substrate 3326 Sources: https://www.genome.jp/kegg/drug/br08309.html	yes [Km 10 uM]
OCT2 348	substrate 3326 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNzQzMTIyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE3MCJ9fQ%3D%3D	yes [Km 2.6 uM]
CYP2D6 1193	substrate 3326 Sources: https://go.drugbank.com/drugs/DB00468	yes
CYP3A5 391	substrate 3326 Sources: https://go.drugbank.com/drugs/DB00468	yes
CYP3A7 110	substrate 3326 Sources: https://go.drugbank.com/drugs/DB00468	yes
OCT1 322	substrate 3326 Sources: https://go.drugbank.com/drugs/DB00468	yes
CYP3A4 1709	substrate 3326 Sources: https://www.genome.jp/kegg/drug/br08309.html, https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021799s008lbl.pdf	yes	yes (co-administration study) Comment: Coadministration of Ketoconazole increased Quinine AUC by 45% and decreased a mean oral clearance of Quinine by 31%. Sources: https://www.genome.jp/kegg/drug/br08309.html, https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021799s008lbl.pdf

Sourcing

Vendor/Aggregator	ID	URL
ChEMBL	CHEMBL3707332
ChemIDplus	146407	https://chem.nlm.nih.gov/chemidplus/id/0000146407
PubChem	56840788	https://pubchem.ncbi.nlm.nih.gov/compound/56840788
Wikidata	Q27282158

Substance Class	Chemical Created by `admin` on `Thu Jul 06 01:56:32 UTC 2023` Edited by `admin` on `Thu Jul 06 01:56:32 UTC 2023`
Record UNII	KAU4V10S2I
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

QUININE ASCORBATE

Official Name

English

QUININE ASCORBATE [MART.]

Common Name

English

L-ASCORBIC ACID, COMPOUND WITH QUININE (2:1)

Common Name

English

QUININE ASCORBATE [USAN]

Common Name

English

L-ASCORBIC ACID, COMPOUND WITH (8.ALPHA.,9R)-6'-METHOXYCINCHONAN-9-OL (2:1)

Common Name

English

Classification Tree Code System Code

CFR

21 CFR 310.547